Enteric glial senescence drives inflammaging by uncoupling serotonin‑dependent vagal tone
Hypothesis
We hypothesize that aging‑associated senescence of enteric glial cells (EGCs) disrupts the microbiota‑SCFA‑TPH1 axis by impairing glutamate‑mediated support of enterochromaffin (EC) cells, thereby lowering colonic serotonin production and weakening vagal afferent signaling to the brain.
Mechanistic Rationale
In the healthy gut, EGCs release trophic factors such as GDNF and S100B and modulate intracellular calcium waves that enhance TPH1 activity in neighboring EC cells without altering EC cell numbers [https://pmc.ncbi.nlm.nih.gov/articles/PMC4396604/]. With age, EGCs accumulate DNA damage and adopt a senescence‑associated secretory phenotype (SASP) marked by IL‑6, TNFα, and MMPs [https://pmc.ncbi.nlm.nih.gov/articles/PMC10253713/]. This SASP suppresses TPH1 transcription via NF‑κB–dependent pathways and alters the mucosal barrier, reducing SCFA‑producing bacteria and further diminishing butyrate‑driven TPH1 upregulation.
Consequently, colonic 5‑HT release falls, decreasing activation of 5‑HT3 receptors on vagal afferents. Reduced vagal signaling diminishes anti‑inflammatory cholinergic feedback to the periphery, allowing systemic inflammaging to progress. Simultaneously, lowered serotonin slows colonic motility, fostering dysbiosis that fuels more SASP‑inducing microbial metabolites—a vicious cycle.
Testable Predictions
- Marker correlation – In murine models, colonic EGC p16^INK4a^ positivity will inversely correlate with luminal 5‑HT concentrations, vagal nerve firing rates (measured ex vivo), and plasma IL‑6/TNFα levels.
- Senolytic rescue – Treatment with a senolytic regimen (dasatinib + quercetin) will reduce EGC senescence markers, restore colonic 5‑HT production, increase vagal afferent activity, and lower circulating inflammatory cytokines compared with vehicle controls.
- Microbiota link – Fecal transplants from senolytic‑treated aged mice into germ‑aged recipients will improve SCFA levels and 5‑HT output, indicating that the EGC‑driven milieu shapes the microbiome.
- Specificity control – Genetic ablation of p16^INK4a^ specifically in EGCs (using Sox10‑CreERT2) will mimic senolytic benefits, whereas pan‑cellular senolysis will not produce additional improvements, confirming EGCs as the pivotal node.
Falsifiability
If senolytic clearance of EGC senescence fails to elevate colonic 5‑HT, enhance vagal signaling, or reduce systemic inflammation despite verified reduction in p16^INK4a^‑positive EGCs, the hypothesis is refuted. Likewise, if ectopic overexpression of TPH1 in EC cells does not compensate for EGC senescence‑induced vagal hypoactivity, the proposed glial‑EC coupling mechanism would be insufficient.
Implications
Targeting EGC senescence offers a dual‑action strategy: restoring gut‑derived serotonergic tone to the brain while ameliorating peripheral inflammaging. Because the ENS is readily accessible via biopsy or endoscopic sampling, EGC senescence could serve as a biomarker‑intervention axis for aging‑related neuropsychiatric and metabolic disorders.